Global Malaria Burden
228,000,000 cases of malaria annually
405,000 deaths per year
Current gold standard testing, including rapid diagnostic tests and microscopy, can miss malaria cases. This is particularly a problem in patients that have low levels of malaria parasite at the time of the test or when diagnosing pregnant women.
Patients that have been misdiagnosed, and told they do not have malaria when they do, are not only lacking treatment for an infectious disease that could result in severe adverse health outcomes, but they also act as a reservoir for future malaria transmission.
Current ultra-sensitive diagnostics on the market are not designed to be robust enough for deployment in rural Africa and other malaria-endemic regions.
The Illucidx Malaria DX Solution
Illucidx team members from the University of Calgary have collaborated with partners in Ethiopia to advance malaria diagnostics for years. We have seen firsthand what is feasible and what is not when deploying diagnostics in remote malaria-endemic regions of the world.
The solution we are developing is 100 to 1000 times more sensitive than the current field-deployed diagnostics. It is specifically designed to be robust and simple to use with minimal training and laboratory infrastructure; dedicated laboratory space and consistent electricity will not be required. Our test is shelf-stable, allowing it to be brought to point-of-care with detection levels comparable to those of laboratory-based tests. We intimately understand that all of this must come at a cost that is economical and practical for large scale deployment in low and middle-income countries.
We are currently perfecting moving our diagnostic chemistry to a cartridge-based system. If you have any questions or think this solution would provide value to you, please don't hesitate to contact us.